In vitro antifungal activity of silver nanoparticles against ocular pathogenic filamentous fungi

Journal of Ocular Pharmacology and Therapeutics

Volumn 29, Issue 2, 2013, Pages 270-274

  Xu, Yan ^a   Gao, Chuanwen ^a   Li, Xiaohua ^b   He, Yi ^a   Zhou, Lutan ^a   Pang, Guangren ^a   Sun, Shengtao ^a  

^a Henan Eye Institute   (China)

^b Department of Ophthalmology   (China)

Author keywords

[No Author keywords available]

Indexed keywords

NATAMYCIN; SILVER NANOPARTICLE;

ALTERNARIA ALTERNATA; ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIGER; ASPERGILLUS VERSICOLOR; CONTROLLED STUDY; DATA ANALYSIS SOFTWARE; FUNGUS ISOLATION; FUSARIUM MONILIFORME; FUSARIUM OXYSPORUM; FUSARIUM SOLANI; HUMAN; IN VITRO STUDY; KERATOMYCOSIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

ANTIFUNGAL AGENTS; EYE INFECTIONS, FUNGAL; FUNGI; HUMANS; MICROBIAL SENSITIVITY TESTS; NANOPARTICLES; SILVER;

EID: 84875036943     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2012.0155     Document Type: Article

References (36)

1. Sun, X.G., Wang, Z.X., Wang, Z.Q., Luo, S.Y., & Li, R. Ocular fungal isolates and antifungal susceptibility in northern China. Am. J. Ophthalmol. 143:131-133, 2007.
2. Xie, L., Dong, X., & Shi, W. Treatment of fungal keratitis by penetrating keratoplasty. Br. J. Ophthalmol. 85:1070-1074, 2001.
3. Zhong, W.X., Sun, S.Y., Zhao, J., Shi, W.Y., & Xie, L.X. Retrospective study of suppurative keratitis in 1054 patients. Chin. J. Ophthalmol. 43:245-250, 2007.
4. Xu, Y., Pang, G.R., Zhao, D.Q., et al. Activity of butenafine against ocular pathogenic filamentous fungi in vitro. Chin. J. Ophthalmol. 46:38-42, 2010.
5. Xu, Y., Pang, G.R., Gao, C.W., et al. Comparison of the activities of silver nitrate with those of three antifungal agents against ocular pathogenic fungi in vitro. Chin. J. Ophthalmol. 45:730-735, 2009.
6. Rao, S., Madhavan, H., Rao, G., & Padmanabhan, P. Fluconazole in filamentous fungal keratitis. Cornea 16:64-71, 1997.
7. Xie, L., Zhai, H., Zhao, J., et al. Antifungal susceptibility for common pathogens of fungal keratitis in Shandong Province, China. Am. J. Ophthalmol. 146:260-265, 2008.
8. Thomas, P.A. Current perspectives on ophthalmic mycoses. Clin. Microbiol. Rev. 16:730-797, 2003.
9. Srinivasan, M. Fungal keratitis. Curr. Opin. Ophthalmol. 15:321-327, 2004.
10. O'Day, D.M., Head, W.S., Robinson, R.D., & Clanton, J.A. Corneal penetration of topical amphotericin B and natamycin. Curr. Eye Res. 5:877-882, 1986.
11. Xu, Y., Pang, G.R., Zhao, D.Q., et al. In vitro activity of thimerosal against ocular pathogenic fungi. Antimicrob. Agents Chemother. 54:536-539, 2010.
12. Xu, Y., Pang, G.R., Gao, C.W., et al. In vitro comparison of the efficacies of natamycin and silver nitrate against ocular fungi. Antimicrob. Agents Chemother. 53:1636-1638, 2009.
13. Lalitha, P., Shapiro, B.L., Srinivasan, M., et al. Antimicrobial susceptibility of Fusarium, Aspergillus, and other filamentous fungi isolated from keratitis. Arch. Ophthalmol. 125:789-793, 2007.
14. Mehta, H., Mehta, H.B., Garg, P., & Kodial, H. Voriconazole for the treatment of refractory Aspergillus fumigatus keratitis. Indian J. Ophthalmol. 56:243-245, 2008.
15. Klasen, H.J. Historical review of the use of silver in the treatment of burns. I. Early uses. Burns 26:117-130, 2000.
16. Lansdown, A.B. Silver. 1. Its antibacterial properties and mechanism of action. J. Wound Care 11:125-130, 2002.
17. Crede, C.S.R. Die verhutung der augenentzundung der neugeborenen. Arch. Gynaekol. 17:50-53, 1881.
18. Silver, S. Bacterial silver resistance: molecular biology and uses and misuses of silver compounds. FEMS Microbiol. Rev. 7:341-353, 2003.
19. Panacek, A., Kvitek, L., Prucek, R., et al. Silver colloid nanoparticles: synthesis, characterization, and their antibacterial activity. J. Phys. Chem. B 110:16248-16253, 2006.
20. Marambio-Jones, C., & Hoek, E.M.V. A review of the antibacterial effects of silver nanomaterials and potential implications for human health and the environment. J. Nanopart. Res. 12:1531-1551, 2010.
21. AshaRani, P.V., Mun, G.L.K, Hande, M.P., & Valiyaveettil, S. Cytotoxicity and genotoxicity of silver nanoparticles in human cells. ACS Nano. 3:279-290, 2009.
22. Carlson, C., Hussain, S.M., Schrand, A.M., et al. Unique cellular interaction of silver nanoparticles: size-dependent generation of reactive oxygen species. J. Phys. Chem. B 112:13608-13619, 2008.
23. Panacek, A., Kolar, M., Vecerova, R.A., et al. Antifungal activity of silver nanoparticles against Candida spp. Biomaterials 30:6333-6340, 2009.
24. Kim, K.J., Sung, W.S., Moon, S.K., et al. Antifungal effect of silver nanoparticles on dermatophytes. J. Microbiol. Biotechnol. 18:1482-1484, 2008.
25. Kim, K.J., Sung, W.S., Suh, B.K., et al. Antifungal activity and mode of action of silver nanoparticles on Candida albicans. Biometals 22:235-242, 2009.
26. Wang, D.L. Medical Mycology-Guide to Laboratory Examination. Beijing: People's Medical Publishing House; 2005.
27. Wu, S.X. Identification Manual of Medical Fungi. Beijing: Chinese Academy of Medical Sciences & Peking Union Medical College Press; 2005.
28. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi; approved standard. NCCLS Document M38-A 2002. Wayne, PA: NCCLS; 2002.
29. Lalitha, P., Vijaykumar, R., Prajna, N.V., & Fothergill, A.W. In vitro natamycin susceptibility of ocular isolates of Fusarium and Aspergillus species: comparison of commercially formulated natamycin eye drops to pharmaceuticalgrade powder. J. Clin. Microbiol. 46:3477-3478, 2008.
30. Pradhan, L., Sharma, S., Nalamada, S., et al. Natamycin in the treatment of keratomycosis: correlation of treatment outcome and in vitro susceptibility of fungal isolates. Indian J. Ophthalmol. 59:512-514, 2011.
31. Morones, J.R., Elechiguerra, J.L., Camacho, A., et al. The bactericidal effect of silver nanoparticles. Nanotechnology 16:2346-2353, 2005.
32. Chen, X., & Schluesener, H. Nanosilver: a nanoproduct in medical application. Toxicol. Lett. 176:1-12, 2008.
33. Choi, O., & Hu, Z. Size dependent and reactive oxygen species related nanosilver toxicity to nitrifying bacteria. Environ. Sci. Technol. 42:4583-4588, 2008.
34. Jose, R.M., Jose, L.E., Alejandra, C., et al. The bactericidal effect of silver nanoparticles. Nanotechnology 16:2346-2353, 2005.
35. Lok, C.N., Ho, C.M., Chen, R., et al. Proteomic analysis of the mode of antibacterial action of silver nanoparticles. J. Proteome Res. 5:916-924, 2006.
36. Santoro, C.M., Duchsherer, N.L., & Grainger, D.W. Antimicrobial efficacy and ocular cell toxicity from silver nanoparticles. Nanobiotechnology 3:55-65, 2007.